New brochure for physicians interested in TIF

1. Advanced Surgical Instrumentation
The EsophyX device represents a decade of innovative technology evolution. A surgical instrument,
designed by surgeons, creates a fundoplication that rivals laparoscopic surgery. Iterative engineering
design elements of EsophyX were created to achieve overall restoration of the antireux barrier.
Helical Retractor
Tissue Mold Able to group and pull tissue
Strong flexible design for
easy, safe insertion. Targets &
molds the new created valve.
to create 3-5 cm flap valve.
A Partnership
Invaginator
in FRONTLINE Surgical Management of GERD
Engage and lengthen lower
Stylet esophagus and reduce hiatal
For rapid accurate hernia if present.
placement of fasteners.
EsophyX™2 TIF™ 2
Elbow
Complete maneuverability Z-line Window
within the stomach. Accurate identification and
location of new valve.
EsophyX™ 2 is a multi-faceted surgical instrument for
antireflux surgery with advanced fastener delivery
• Functions as an extension of the surgeons hand
Before EsophyX • Proprietary H fasteners to create serosa-to-serosa fusion
• Multiple fastener deployment for full valve reconstruction
• Customize valve construction per patient anatomy
EsophyX will dramatically expand the number of patients seeking
a permanent anatomical repair by lowering the surgical hurdle.
• Unique Surgical Approach
12 mo after EsophyX
EsophyX increases patient options and allows earlier intervention.
• Clinically Safe and Effective
8210 154th Ave NE · Redmond, WA 98052 · Tel (425) 307-9200
Fax (425) 307-9201 · www.endogastricsolutions.com
• Advanced Surgical Instrumentation
EsophyX™ Getting it Right
© 2008, EndoGastric Solutions. All rights reserved. EndoGastric Solutions,
StomaphyX, EsophyX, SerosaFuse are trade marks of EndoGastric Solutions, Inc.
EsophyX is FDA cleared and CE marked, and available in the USA and the European Union. PN: C00716-01 B

2. Unique Surgical Approach Clinically Safe and Effective
EsophyX TIF Front LineSurgicalManagement
“Front Line Surgical Management” EsophyX™ Getting it Right
Mild
Mild GERD
GERD
Severe
Severe GERD
GERD 85% of patients remain off daily PPIs one year after EsophyX™ TIF 85%
Lifestyle Change Pharmaceutical Surgical
• Less invasive, no incision or dissection
The TIF surgical procedure using the advanced surgical instrumentation of EsophyX you are able to have • Reducing Hiatal Hernias less than 2 cm
now a FRONTLINE SURGICAL MANAGEMENT of GERD. The EsophyX device enables surgeons and advanced
interventional gastroenterologists to offer their patients substantive anatomical repair without incisions
• Stopping and reducing esophagitis
(no skin or internal dissection) to intervene earlier and change patients lives. • Significantly improving patient quality of life
EsophyX™ Advantages *P < 0.01 N = 65
Transoral Approach - TIF Surgical Procedure
• Transoral truly non-invasive, incisionless
• TIF is an evolution of current surgical procedures
• Based upon proven surgical principles
• TIF has the ability to “reconstruct” the major
components of the antireux barrier
• Adaptable, repeatable, adjustable
• Future options not limited The EsophyX™-TIF1.0 procedure resulted in a 53% increase (P<0.001) in
• Serosa-to-serosa fusion mean LES resting pressure (18 mm Hg post-TIF vs. 13 mm Hg pre-TIF)
Delivers similar benets of time proven surgical laparoscopic fundoplication
Vector Volume
In TIF 2.0, the esophagus “emerges” from the repair reecting the
fact that the stomach has been wrapped around the esophagus. The
 
appearance and location of this valve relative to the EGJ on vector
volume analysis is very similar to that seen for Nissen fundoplication. 12 mo Post - TIF Pre - TIF off PPIs
Reference: Stein HJ, DeMeester TR, Naspetti R, Jamieson J, Perry RE. Three-dimensional
imaging of the lower esophageal sphincter in gastroesophageal reux disease. Ann
Surg 1991; 214; 374-383.
12 months after the EsophyX™ TIF1.0 procedure, 40-65% of patients were able to consume all foods that trigger
heartburn without symptoms while off their PPIs in comparison to 5-40% of patients before the procedure.
Nissen vs. TIF 2